Sean Mackay
Chief Executive Officer, Co-Founder, and Board Director

Sean Mackay is an experienced entrepreneur passionate about applying life sciences and information technology to improve healthcare delivery. He co-founded and leads IsoPlexis, a venture-backed startup focused on accelerating the fight against cancer using our predictive patient profiling platform. He has led company through foundational licensing with Yale and Caltech, venture capital financing, and building out its fantastic team, while developing applications, products, and collaborations. Previously, he also helped incubate Kleiner Perkins-backed Lifesquare, which connected patients, payers, and providers through sharing essential healthcare information. At Lifesquare, he generated business development and strategic initiatives related to partnerships across the healthcare ecosystem. Through work at Lazard and with several early-stage ventures, he developed deep experience in structuring and financing life sciences and medical device and technology companies. Sean also helped multiple public and private biotechnology and medical technology companies to manage times of strategic change.

Jing Zhou, M.D., Ph.D.
VP of Translational Medicine

Jing Zhou is the VP of Translational Medicine at IsoPlexis. Working with the talented multidisciplinary teams at the company, she is responsible for developing single-cell assays for precisely profiling the functional properties and heterogeneity of immune cells using IsoPlexis' IsoCode proteomics platform, and for discovery of predictive biomarkers as correlates of patient outcome to immunotherapies. Since joining IsoPlexis in 2015, she has led multiple studies with various biopharma and trial center leaders, particularly in the immuno-oncology space, to develop single-cell polyfunctional metrics that can distinguish and predict patient response to CAR-T and antibody-based cancer immunotherapies. These novel findings have led to numerous presentations at prestigious scientific conferences including AACR, ASH, ASCO, SITC, FOCiS and high-impact publications in journals such as Blood and JITC. Prior to IsoPlexis, she was an immunologist at the Yale School of Medicine with expertise in defining phenotype and functionality of immune cells in diseased and healthy settings, with a good track record of 30+ scientific publications in leading journals. Jing earned her medical degree in Clinical Medicine from Bengbu Medical College, M.S. and Ph.D. in Immunology from Shanghai Jiao Tong University, and has been the principal investigator of NIH, AHA and Yale University grants.

Verna Siu
VP of Sales Operations and Business Development

Verna Siu is the VP of Sales Operations and Business Development at IsoPlexis. She held various Sales Operations and Financial Planning positions in both start-up medical device company to billion-dollar consumer product corporations.  She specializes in sales strategic planning with strong business acumen and entrepreneur mindset, successfully led sales analytical effort in a medical device startup, SurgiQuest, and drove double digit annual growth on a flagship product line.  SurgiQuest, a pre-IPO medical device enterprise, was acquired for $265 million.

Patrick Paczkowski, Ph.D.
VP of Software

Patrick Paczkowski is the VP of Software at IsoPlexis. He joined IsoPlexis as one of the first employees in 2014, after prior startup experience originating from his doctoral work at Yale University. During his time at IsoPlexis, he has turned IsoSpeak – the company’s data processing and bioinformatics software – from a vision to a fully automated and developed product. Patrick oversees all software development at IsoPlexis, including novel image processing algorithms, bioinformatics tools, automation firmware, internal QC tools, and software to support next-gen R&D projects. In addition, he leads the bioinformatics team in their analytics support of single-cell data obtained from IsoPlexis’ IsoCode device, and manages the development and maintenance of the IT infrastructure at the company. He holds several patents and is the lead author of multiple scientific, peer-reviewed publications spanning both the areas of computer science and single-cell analysis. He holds a Ph.D. in Computer Science from Yale University and received dual B.S. degrees in Mathematics and Computer Science from Duke University.

David Choiniere
VP of Sales

David Choiniere is the VP of Sales for IsoPlexis. David has 30 years of experience in life science research and sales. He was VP of Sales at IntelliCyt and as the 7th employee, helped build the sales organization and processes for the company, building the market share of their unique screening technology in the drug discovery, biologics, and immuno-therapy spaces, through Intellicyt’s successful acquisition by Sartorius Corporation. Prior to that, David held sales and management roles at Molecular Devices, Arcturus, and Zymed laboratories. Before his sales career, David did graduate work and was a lab manager at Georgetown University and has a BA in Biology from the University of Virginia.

Rui Zheng, Ph.D.
VP of Innovation

Rui Zheng is VP of Innovation at IsoPlexis. Since joining in 2016, Rui has been the lead systems engineer for IsoPlexis’ IsoLight automation platform. 10+ years biomedical chemistry / instrumentation R&D experience including 5 years with Life Technology / Thermo Fisher’s Ion Torrent product development team, where he was the key design engineer of multiple commercialized Next-Gen Sequencing consumables and automation platforms. Rui was the inventor of the product enabling patents of the ION CHEF system. He also supported a number of manufacturing automation projects and cross department innovation programs. He was a core member of the Ion Torrent Innovation Trust Team and Life Technologies’ top talent pool program. Rui holds a Ph.D. in Biomedical Engineering from University of Toledo.

Peter Tsiomplikas
VP of Product R&D

Peter is the VP of Product R&D at IsoPlexis. Since he started at IsoPlexis in 2015, he has lead several projects that automate IsoPlexis’ novel assays and consumable manufacturing. He has lead IsoLight development and launch efforts and holds multiple patents for the design of the device and related consumables. Peter was previously employed by PerkinElmer, where he developed liquid handling automated systems for use in diagnostic assay development. Previous to PerkinElmer, he developed durable testing equipment at Instron. Peter has over 10 years of experience in product development and has successfully launched products to a worldwide market. He holds a BS and MS degrees in mechanical engineering from Northeastern University.

Michael Kane
VP of Capital Production

Mike is the VP of Capital Production at IsoPlexis.

Carrie Carter
VP of People Ops

Carrie is the VP of People Ops at IsoPlexis. She is responsible for overseeing team development and talent management, helping lead IsoPlexis through rapid growth. As Chief of Staff, Carrie manages HR, laboratory operations, and grants management. Prior to joining IsoPlexis, she was Business Manager for Clinical Development Group (CDG), acquired by Sarah Cannon Research Institute where she worked as Program Administrator of various clinical / life science groups.

Jonathan Chen
Director of New Collaborations

Jon is the Director of New Collaborations at IsoPlexis and co-inventor of the IsoPlexis technology. Jon’s graduate work at Yale explores the tumor microenvironment and the immune function of single cells. He received his BS in Physiology and Neuroscience with a minor in visual arts at UC San Diego. Jon has published multiple peer-reviewed articles at the interface of oncology and immune mediated diseases.

Unlock the IsoPlexis

Single-Cell Webinar Series 

Your data is in safe hands. View Privacy Policy

Unlock the IsoPlexis

Technology Overview Series

Your data is in safe hands. View Privacy Policy